title

ABLAVAR®-enhanced MRA is an innovative approach to evaluating aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease1,2

A single dose of ABLAVAR® contains the lowest dose of gadolinium of all contrast agents used in MRA*1,3-7 and provides

  • Bright first-pass images and high-resolution, steady-state imaging8
  • Accuracy comparable to XRA9,10
  • Image quality with fewer uninterpretable images than unenhanced MRA or XRA9,10
  • An expanded imaging window of up to 1 hour1,8 allowing for evaluation of the extent and severity of disease9,10
  • Results that may impact diagnosis and change patient management10,11

*Of these agents, only ABLAVAR® is approved for steady-state imaging.

References

1. ABLAVAR® [package insert]. North Billerica, MA: Lantheus Medical Imaging, Inc.;2011. 2. US Food and Drug Administration web site. http://www.fda.gov/drugs. Accessed July 24, 2010. 3. Magnevist® [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2010. 4. Omniscan™ [package insert]. Princeton, NJ: GE Healthcare, Inc.; 2010. 5. MultiHance® [package insert]. Princeton, NJ: Bracco Diagnostics, Inc.; 2010. 6. ProHance® [package insert]. Princeton, NJ: Bracco Diagnostics, Inc.; 2010. 7. Optimark™ [package insert]. St. Louis, MO: Mallinckrodt, Inc.; 2010. 8. Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag. 2008;4(1):1-9. 9. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology. 2005;236(3):825-833. 10. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71-78. 11. Willinek W, Hadizadeh D. Patient management and referrals: impact of high-resolution steady-state MRA with Vasovist. In: Leiner T, Goyen M, Rohrer M, Schönberg S, eds. Clinical Blood Pool MR Imaging. Heidelberg, Germany: Springer Medizin Verlag; 2008:253. 12. Huppertz A, Kroll H, Klessen C, et al. Biphasic blood pool contrast agent-enhanced whole-body MR angiography for treatment planning in patients with significant arterial stenosis. Invest Radiol. 2009;44(7):422-432.